TD Asset Management Inc Purchases 522,512 Shares of AbbVie Inc. $ABBV

TD Asset Management Inc grew its position in AbbVie Inc. (NYSE:ABBV) by 14.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,258,327 shares of the company’s stock after acquiring an additional 522,512 shares during the period. AbbVie comprises about 0.8% of TD Asset Management Inc’s portfolio, making the stock its 26th largest holding. TD Asset Management Inc’s holdings in AbbVie were worth $985,973,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. increased its position in AbbVie by 0.3% during the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of AbbVie by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after acquiring an additional 924,761 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after acquiring an additional 1,517,222 shares during the last quarter. Norges Bank acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $4,288,200,000. Finally, Raymond James Financial Inc. raised its stake in AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after acquiring an additional 2,753,312 shares during the period. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $228.44 on Wednesday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm’s 50-day simple moving average is $224.17 and its 200 day simple moving average is $222.67. The firm has a market cap of $403.92 billion, a price-to-earnings ratio of 96.80, a P/E/G ratio of 0.80 and a beta of 0.35.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the business posted $2.16 EPS. The business’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s payout ratio is currently 293.22%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ABBV shares. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research note on Tuesday, January 20th. Barclays started coverage on shares of AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a report on Tuesday, November 4th. Finally, Piper Sandler boosted their price objective on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $253.15.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Announced a $380 million investment to build two active pharmaceutical ingredient (API) plants at its North Chicago campus to support neuroscience and obesity medicines; construction starts spring 2026 and facilities are expected online by 2029, strengthening domestic supply and “Made in U.S.” manufacturing capacity. Article Title
• Positive Sentiment: FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line, all‑oral, fixed‑duration regimen for previously untreated CLL — a label expansion that can meaningfully support oncology revenue growth. Article Title
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and $275 price target, citing upside from operating leverage and under‑appreciated growth potential — a catalyst that can attract buyers. Article Title
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in bipolar I disorder, a data point that supports the product’s real‑world evidence but is unlikely to move near‑term revenue materially. Article Title
• Neutral Sentiment: Analysts have modestly updated fair‑value models (example: a small move to ~$248.29), reflecting mixed views — positive readthroughs on pipeline and immunology assets offset by caution on execution. Article Title
• Negative Sentiment: Investor concerns about competitive pressure in key franchises and execution risk (integration, manufacturing ramp timelines, and maintaining growth after major product lifecycles) are being highlighted in coverage and may be prompting profit‑taking. Article Title

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.